The Research Of Blocking Target Cyclooxygenase-2 On The Growth Of Laryngeal Carcinoma Cell

ObjectiveCyclooxygenase-2 (COX-2) contributes to development of laryngeal cancer. We can use the COX-2 inhibitors to cure the cancers, but the research of the COX-2 inhibitors on laryngeal cancer is rare. This study was designed to explore the effect of COX-2 inhibitor (celecoxib) on laryngeal cancer cell lines Hep-2.Methodslaryngeal cancer cell lines Hep-2 was treated with the celecoxib in a range of concentrations as single agents. Cell growth inhibition was measured by MTT. After Hep-2 cells were treated by celecoxib with the concentration of 15umol/L, the cell cycle and apoptosis of the cells were measure by flow cytometric analysis. The expressions of relative protein were also examined using western blot.Results(1) The cell growth was inhibited by celecoxib, and such effect showed a concentration-dependent manners in a certain range.(2) Celecoxib significantly induced G1 arrest (P<0.01) and apoptosis (p<0.05).(3) Treated by celecoxib, Hep-2 expressed less p-EGFR and COX-2 than control cells(p<0.05).Conclusions (1)Blocking target COX-2 can inhibit growth of the Hep-2 cell lines.(2) Blocking target COX-2 significantly induced Hep-2 cells G1 arrest and apoptosis to inhibit growing.(3) Blocking target COX-2 reduce the phosphorylation of EGFR and express of COX-2. COX-2 inhibitors may become the new targeting therapy of laryngeal cancer.